Methods and compositions for modification of a HLA locus

1. A genetically modified mammalian cell comprising an endogenous human leukocyte antigen (HLA) class I gene comprising a sequence selected from the group consisting of any one of the nucleotides of SEQ ID NOs:97 to 111 and an endogenous HLA class II gene comprising a sequence selected from the group consisting of any one of the nucleotides of SEQ ID NOs:112 to 115, the genetically modified cell comprising:

(i) a first genomic modification comprising an integrated exogenous nucleotide sequence encoding a chimeric antigen receptor (CAR) or T-cell receptor gene, and

(ii) a second genomic modification comprising an inactivated HLA gene following zinc finger nuclease-mediated cleavage of the active HLA class I gene and/or HLA class II gene with a pair of zinc finger nucleases, each zinc finger nuclease comprising a cleavage domain and the recognition helix regions of the zinc finger proteins designated 18889, which binds to a target site within SEQ ID NO:97; 11881, which binds to a target site within SEQ ID NO:98; 24859, which binds to a target site within SEQ ID NO:99; 25191, which binds to a target site within SEQ ID NO: 100; 25190, which binds to a target site within SEQ ID NO:101; 25316, which binds to a target site within SEQ ID NO:102; 25317, which binds to a target site within SEQ ID NO:103; 15267, which binds to a target site within SEQ ID NO: 104; 15265, which binds to a target site within SEQ ID NO: 105; 17454, which binds to a target site within SEQ ID NO: 106; 17456, which binds to a target site within SEQ ID NO:107; 15296, which binds to a target site within SEQ ID NO:108; 15298, which binds to a target site within SEQ ID NO:109; 25588, which binds to a target site within SEQ ID NO:110; 25589, which binds to a target site within SEQ ID NO:111; 15872, which binds to a target site within SEQ ID NO:112; 15873, which binds to a target site within SEQ ID NO: 113; 15909, which binds to a target site within SEQ ID NO: 114; or 15910, which binds to a target site within SEQ ID NO:115,

wherein the pair of zinc finger nucleases includes 18889 and 18881; 18889 and 24859; 25191 and 25190; 25316 and 25317; 15267 and 15265; 17454 and 17456; 15296 and 15298; 25588 and 25589; 15872 and 15873; or 15909 and 15910;

and wherein the HLA gene is inactivated by the second genomic modification.

2. The genetically modified cell of claim 1 , wherein the HLA class I gene is selected from the group consisting of an HLA A2 gene, an HLA A3 gene, an HLA B gene and an HLC gene.

3. The genetically modified cell of claim 1 , wherein the integrated exogenous nucleotide sequence encodes a CAR.

4. The genetically modified cell of claim 1 , wherein the integrated exogenous nucleotide sequence comprises a TCR gene.

5. The genetically modified cell of claim 1 , wherein a donor sequence is inserted into the inactivated HLA gene following targeted cleavage with the pair of zinc finger nucleases proteins.

6. The genetically modified cell of claim 1 , wherein the CAR targets CD19 (CD19CAR).

7. The genetically modified cell of claim 1 , wherein the cell is a T-cell or a stem cell.

8. The genetically modified cell of claim 7 , wherein the stem cell is a hematopoietic stem cell.

9. The genetically modified cell of claim 1 , further comprising a third genomic modification comprising inactivation of a second gene using one or more zinc finger nucleases.

10. The genetically modified cell of claim 9 , wherein the inactivated second gene is selected from the group consisting of a DBP2 gene; a DRA gene; transporter associated antigen processing (TAP) gene; tapasin gene; class 2 transactivator (CTIIA) gene; regulatory factor X protein 5 (RFX5) gene; T-cell receptor alpha (TRAC) or a T-cell receptor beta (TRBC) gene.

11. A pharmaceutical composition comprising the genetically modified mammalian cell of claim 1 .